Export

EN
FR
Adalimumab
Essential medicine status
General description

INN
Adalimumab
ATC codes
L04AB04
Medicine type
Biological agent
EML status history
First added in 2019 (TRS 1021) for Axial spondyloarthritis
Added in 2019 (TRS 1021) for Rheumatoid arthritis
Added in 2019 (TRS 1021) for Crohn disease site
Wikipedia
Adalimumab
DrugBank
Adalimumab
Recommendations
Section
Immunomodulators for non-malignant disease
  • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
Indications
Rheumatoid arthritis Axial spondyloarthritis Crohn disease site
Section
Medicines for juvenile joint diseases
  • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL
Indications
Juvenile idiopathic arthritis
Section
Dermatological medicines > Medicines affecting skin differentiation and proliferation
  • Parenteral > General injections > SC: 10 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.2 mL mL in pre-filled syringe or pre-filled pen.; 20 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.4 mL mL in pre-filled syringe or pre-filled pen.; 40 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.; 80 mg per 0.8 mL mL in pre-filled syringe or pre-filled pen.
Indications
Psoriasis of unspecified type